Search

Displaying results 4061 - 4070 of 8700 in total
  1. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  2. Drug

    Abciximab

    go.drugbank.com/drugs/DB00054
    ApprovedWithdrawn

    It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. … Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules

    Categories: Glycoprotein IIb/IIIa Receptor-directed Monoclonal Antibodies
  3. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    Fitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety.

  4. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. … CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease.

  5. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    [L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Nevirapine

    go.drugbank.com/drugs/DB00238
    ApprovedInvestigational

    A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Temocapril

    go.drugbank.com/drugs/DB08836
    Investigational

    Temocapril can also be used in hemodialysis patients without risk of serious accumulation. … Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.

  9. Target

    Human Retinoid X Receptors (RXRs)

    go.drugbank.com/bio_entities/BE0010096
    TargetHumans

    Receptor for retinoic acid. … Receptor for retinoic acid.

    Polypeptides: Retinoic acid receptor RXR-alpha, Retinoic acid receptor RXR-betaSynonyms: Retinoid X receptor alpha, Retinoid X receptor beta
  10. Target

    Peroxisome proliferator-activated receptors

    go.drugbank.com/bio_entities/BE0010120
    TargetHumans and other mammals

    May be required for the propagation of clock information to metabolic pathways regulated by PER2 … Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids.

    Polypeptides: Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor deltaSynonyms: Nuclear hormone receptor 1, Nuclear receptor subfamily 1 group C member 1